Combination of Nivolumab and Ipilimumab Improved Overall Survival For Advanced Melanoma Patients

?WASHINGTON — Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had improved overall survival compared with those who received only ipilimumab and appeared to have more favorable survival outcomes compared with those who received nivolumab, according to results from the phase III CheckMate 067 clinical trial presented here at […]

TERT Inhibitors Show Potential in Treatment of Uncommon Type of Melanoma

Scientists reported a significant genetic association linked to an aggressive form of melanoma in a study (“Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma”) published in Genome Research.

IDO Inhibitor Increases Pembrolizumab Response in Melanoma

Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate (ORR) of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.

Common Cold Virus Improves Response with Immunotherapy in Advanced Melanoma

Half of patients with advanced melanoma responded to a novel combination treatment consisting of the common cold virus with an immune checkpoint inhibitor, in a recent phase Ib clinical trial presented April 4 at the American Association for Cancer Research (AACR) Annual Meeting.

Cancer in the News

Feature Articles

Adding Coxsackievirus to Ipilimumab Displays Durable Antitumor Activity in Advanced Melanoma

Adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to ipilimumab (Yervoy) yielded an overall response rate (ORR) of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Combined immunotherapy shows early promise in advanced melanoma

Patients with advanced melanoma derived benefit from a combination of ipilimumab and Coxsackievirus A21, according to a phase 1b clinical trial presented at the American Association for Cancer Research Annual Meeting.

Read the full story

Posted in Melanoma In The News, Information

Early-stage Eye Melanoma Trial Tests Less-invasive Treatment Approach

Patients with ocular melanoma, a type of melanoma that develops in the eye, have a potentially new and groundbreaking treatment option being assessed in a Phase 1 clinical trial.

Read the full story

Posted in Melanoma In The News, Information

Updated Melanoma Survival Data for Opdivo + Yervoy Presented at AACR 2017

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) —two immunotherapies developed by Bristol-Myers Squibb —demonstrated improved survival compared to nivolumab alonein patients with previously untreated advanced melanoma in a recent phase III study.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories